Longevity & Bioidentical Hormones Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009 May;94(5):1732-9. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 Aug;90(8):871-6. Besson A, Salemi S, Gallati S, et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003 Aug;88(8):3664- 7. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004 Jan;89(1):114-120. Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004 Jan 27;62(2):188-193. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007 Dec 4;116(23):2694-701. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 Jul;89(7):3313-3318. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007 Feb;30(2):234-238. Hak AE, Witteman JC, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-3639. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med. 2007 Nov 12;167(20):2249-54. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-1665. Asvold BO, Bjøro T, Nilsen TI, et al. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. Arch Intern Med. 2008 Apr 28;168(8):855-60. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008 Jun 9;168(11):1174-80. Schumacher M, Guennoun R, Ghoumari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev. 2007 Jun;28(4):387-439. Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 2002 Jan;143(1):205-212. Enomoto M, Adachi H, Fukami A, et al. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). J Am Geriatr Soc. 2008 Jun;56(6):994-998. Fukui M, Kitagawa Y, Nakamura N, et al. Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. Atherosclerosis. 2005 Aug;181(2):339-344. New study finds removing ovaries during hysterectomy increases risk of death, outweighs benefits. Business Wire. 2009 April 20. Accessed from http://www.businesswire.com/news/home/20090420005411/en/Study-Finds- Removing-Ovaries-Hysterectomy-Increases-Risk Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009 May;113(5):1027-37. Shoupe D, Parker WH, Broder MS, et al. Elective oophorectomy for benign gynecological disorders. Menopause. 2007 May-Jun;14(3 Pt 2):580-585. Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol. 2005 May 17;45(10):1603-8. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009 Jan-Feb;16(1):15-23. Parker WH, Manson JE. Oophorectomy and cardiovascular mortality: Is there a link? Menopause. 2009 Jan-Feb;16(1):1-2. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008 Jan;93(1):68-75. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006 Jun;154(6):899-906. Rice D, Brannigan RE, Campbell RK, et al. Men's health, low testosterone, and diabetes: individualized treatment and a multidisciplinary approach. Diabetes Educ. 2008 Nov-Dec;34 Suppl 5:97S-112S. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995 Apr 5;87(7):517-23. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002 Nov 6;288(17):2123-2129. Harden CL. The mysterious effect of reproductive hormones on cognitive function: scientific knowledge in search of an application. J Gend Specif Med. 2000 Oct;3(7):33- 37. Loret De Mola JR. Effects of estrogen use on the risk of alzheimer's disease. Biomedicina. 2000 Jan;3(1):6-7. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol. 2008 Sep;51(3):564-580. Saunders-Pullman RJ. Another potential benefit from HRT: Slowing Parkinson's. Geriatrics. 1998 Jun;53(6):91. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006 Jan;27(1):57-64. Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009 Nov;122(11):1016-1022. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25- hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008 Jun 23;168(12):1340-9. Review of WHI & HERS trials Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril. 2005 Dec;84(6):1589-1601. Gambrell RD. The women's health initiative reports: Critical review of the findings. The Female Patient. 2004;29:25-41. Mishell DR, McNeille LG. Hormone Therapy and Coronary Heart Disease: Evolving evidence from clinical trials. J of Family Practice. 2007 Nov;15(2):S1-S6. Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004 Jul;19(7):791-804. Wood MJ, Cox JL. HRT to prevent cardiovascular disease. What studies show, how to advise patients. Postgrad Med. 2000 Sep 1;108(3):59-60, 63-6, 69-72. Brzyski RG. Hormone replacement therapy and cardiovascular disease. Biomedicina. 2000 Jan;3(1):126-128. Dubey RK, Jackson EK, Gillespie DG, et al. Medroxyprogesterone abrogates the inhibitory effects of estradiol on vascular smooth muscle cells by preventing estradiol metabolism. Hypertension. 2008 Apr;51(4):1197-202. Booth EA, Lucchesi BR. Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1408- 15. Review of Different BHRT Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health. 2007 Jun;16(5):600-631. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl. 1980;233:17-27. Lauritzen C. Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res. 1987 Nov;19(11):579-584. Head KA. Estriol: safety and efficacy. Altern Med Rev. 1998 Apr;3(2):101-113. Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod. 2000 May;15(5):1028-1036. Teoh H, Quan A, Leung SW, Man RY. Vascular effects of estrone and diethylstilbestrol in porcine coronary arteries. Menopause. 2009 Jan-Feb;16(1):104-109. Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. Menopause. 2005 Jul-Aug;12(4):366-73. Pratt JH, Longcope C. Estriol production rates and breast cancer. J Clin Endocrinol Metab. 1978 Jan;46(1):44-7. Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1977 Jun;37(6):1901-1907. Siiteri PK, Sholtz RI, Cirillo PM, et al. Prospective study of estrogens during pregnancy and risk of breast cancer. Public Health Institute. 2002. Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol. 1995 Sep;62(1):101-106. Nachtigall LE. Bioidentical versus nonbioidentical hormones. Proceedings from the postgraduate course presented prior to the 17th annual meeting of the North American Menopause Society.